Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam
- 1Department of Clinical Pharmacy, School of Pharmacy, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
- 2Department of Pharmacy, Thong Nhat Hospital, Ho Chi Minh City, Vietnam
Abstract
Objectives: To assess the utilization of ceftazidime-avibactam at Thong Nhat Hospital, a national hospital in Vietnam. Methods: A descriptive cross-sectional study was conducted using retrospective data from medical records of inpatients aged ≥ 18 years who received ceftazidime-avibactam for at least 2 days between January 2023 and March 2025 at Thong Nhat Hospital, Vietnam. The appropriateness of ceftazidime-avibactam use was evaluated based on Thong Nhat Hospital’s antibiotic use guideline. The backward conditional method was used to identify factors associated with patient treatment outcomes. Results: A total of 101 patients were included, with a median age of 78 years (68−86). Respiratory and bloodstream infections were the most common types, accounting for 84.15% and 44.55% of cases, respectively. Gram-negative bacteria comprised 76.05% of isolates, with Klebsiella pneumoniae (26.47%), Klebsiella aerogenes (18.50%) and Pseudomonas aeruginosa (10.50%) being the most frequent. The susceptibility rate to ceftazidime-avibactam was 71.43% for Klebsiella pneumoniae, 95.65% for Klebsiella aerogenes and 42.86% for Pseudomonas aeruginosa. OXA-48 was the most detected carbapenemase gene (37.84%). The overall appropriateness rate of ceftazidime-avibactam use was 70.30%. The treatment success rate was 39.60%. Treatment in the intensive care unit was associated with decreased treatment success, while comorbid heart failure showed a potential association. Conclusions: The treatment success rate with ceftazidime-avibactam in this study was relatively low. Continuous surveillance of microbiological profiles and antibiotic resistance, particularly to ceftazidime-avibactam, is essential to better guide the management of drug-resistant Gram-negative infections at the hospital.
Related
- Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect
- Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam
- Characterization of KPC-287 conferring high-level ceftazidime–avibactam resistance in an ST11-KL64 Klebsiella pneumoniae isolate
- Microbiological Spectrum and Antimicrobial Resistance Patterns in Tubo-Ovarian Abscesses Managed by Surgery or Drainage at a Tertiary Hospital in Vietnam: A Retrospective Case Series.
- The effect of intravenous dexamethasone in supraclavicular brachial plexus block at Halibet National Referral Hospital, Eritrea 2024–2025: A randomized clinical trial
BibTeX
@article{van2026investigation,
title = {{Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam}},
author = {Khue Dang Minh Van and Han Ngoc Bao Pham and An Thi Thanh Nguyen and Nhi Truc Y. Nguyen and Cam Thi Le Pham and Nhan Thi Thanh Dang and Quynh Thi Huong Bui},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0359631},
url = {https://doi.org/10.1371/journal.pone.0359631},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam
AU - Khue Dang Minh Van
AU - Han Ngoc Bao Pham
AU - An Thi Thanh Nguyen
AU - Nhi Truc Y. Nguyen
AU - Cam Thi Le Pham
AU - Nhan Thi Thanh Dang
AU - Quynh Thi Huong Bui
PY - 2026
DA - 2026/10/13
JO - PLOS One
DO - 10.1371/journal.pone.0359631
UR - https://doi.org/10.1371/journal.pone.0359631
AB - Objectives: To assess the utilization of ceftazidime-avibactam at Thong Nhat Hospital, a national hospital in Vietnam. Methods: A descriptive cross-sectional study was conducted using retrospective data from medical records of inpatients aged ≥ 18 years who received ceftazidime-avibactam for at least 2 days between January 2023 and March 2025 at Thong Nhat Hospital, Vietnam. The appropriateness of ceftazidime-avibactam use was evaluated based on Thong Nhat Hospital’s antibiotic use guideline. The backward conditional method was used to identify factors associated with patient treatment outcomes. Results: A total of 101 patients were included, with a median age of 78 years (68−86). Respiratory and bloodstream infections were the most common types, accounting for 84.15% and 44.55% of cases, respectively. Gram-negative bacteria comprised 76.05% of isolates, with Klebsiella pneumoniae (26.47%), Klebsiella aerogenes (18.50%) and Pseudomonas aeruginosa (10.50%) being the most frequent. The susceptibility rate to ceftazidime-avibactam was 71.43% for Klebsiella pneumoniae, 95.65% for Klebsiella aerogenes and 42.86% for Pseudomonas aeruginosa. OXA-48 was the most detected carbapenemase gene (37.84%). The overall appropriateness rate of ceftazidime-avibactam use was 70.30%. The treatment success rate was 39.60%. Treatment in the intensive care unit was associated with decreased treatment success, while comorbid heart failure showed a potential association. Conclusions: The treatment success rate with ceftazidime-avibactam in this study was relatively low. Continuous surveillance of microbiological profiles and antibiotic resistance, particularly to ceftazidime-avibactam, is essential to better guide the management of drug-resistant Gram-negative infections at the hospital.
SN - 1932-6203
ER -